CA2930584A1 — Ebna1 inhibitors and their method of use
Assigned to Wistar Institute of Anatomy and Biology · Expires 2015-05-21 · 11y expired
What this patent protects
The present invention provides in one aspect compounds of formula (I), which are EBNA1 inhibitors. In certain embodiments, the compounds of the invention are useful for the treatment of diseases caused by EBNA1 activity. In certain embodiments, the compounds of the invention are …
USPTO Abstract
The present invention provides in one aspect compounds of formula (I), which are EBNA1 inhibitors. In certain embodiments, the compounds of the invention are useful for the treatment of diseases caused by EBNA1 activity. In certain embodiments, the compounds of the invention are useful for treatment of diseases caused by latent and/or lytic Epstein-Barr Virus (EBV) infection. In certain embodiments, the compounds of the invention are useful for treating diseases such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.